Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.1016/J.RIDD.2022.104338 | ||||
| Año | 2022 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Background: Despite the increasing number of clinical trials involving children with neurodevelopmental disorders, appropriate and objective outcome measures for behavioral symptoms are still required.Aim: This study assessed the agreement between parents' and clinical researchers' ratings of behavioral problem severity in children with fragile X syndrome (FXS) and chromosome 15 imprinting disorders.Methods and Procedures: The cohort comprised 123 children (64% males), aged 3-17 years, with FXS (n = 79), Prader-Willi (PWS; n = 19), Angelman (AS; n = 15), and Chromosome 15q duplication (n = 10) syndromes. Specific items from the Autism Diagnostic Observation ScheduleSecond Edition and Aberrant Behavior Checklist-Community Edition mapping to corresponding behavioral domains were selected ad-hoc, to assess behavioral problems. Outcomes and Results: Inter-rater agreement for the cohort was slight for self-injury (Intraclass Correlation Coefficient (ICC) = 0.12), fair for tantrums/aggression (0.24) and mannerisms/stereotypies (0.25), and moderate for hyperactivity (0.48). When stratified by diagnosis, ICC ranged from poor (0; self-injury, AS and PWS) to substantial (0.48; hyperactivity, females with FXS).Conclusions and Implications: The high level of inter-rater disagreement across most domains suggests that parents' and researchers' assessments led to discrepant appraisal of behavioral problem severity. These findings have implications for treatment targets and outcome measure selection in clinical trials, supporting a multi-informant approach.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Arpone, Marta | Mujer |
Royal Childrens Hosp - Australia
Univ Melbourne - Australia Royal Children's Hospital, Melbourne - Australia Faculty of Medicine, Dentistry and Health Sciences - Australia |
| 2 | Bretherton, Lesley | - |
Royal Childrens Hosp - Australia
Royal Children's Hospital, Melbourne - Australia |
| 3 | Amor, D. | Hombre |
Univ Melbourne - Australia
Royal Childrens Hosp - Australia Faculty of Medicine, Dentistry and Health Sciences - Australia Royal Children's Hospital, Melbourne - Australia |
| 4 | Hearps, Stephen J. C. | Hombre |
Royal Childrens Hosp - Australia
Univ Melbourne - Australia Royal Children's Hospital, Melbourne - Australia Faculty of Medicine, Dentistry and Health Sciences - Australia |
| 5 | Rogers, Carolyn | Mujer |
Genet Learning Disabil Serv - Australia
Hunter Health - Australia |
| 6 | Field, Michael J. | Hombre |
Genet Learning Disabil Serv - Australia
Hunter Health - Australia |
| 7 | Hunter, Matthew F. | Hombre |
Monash Hlth - Australia
MONASH UNIV - Australia Monash Health - Australia Faculty of Medicine, Nursing and Health Sciences - Australia Faculty of Medicine, Dentistry and Health Sciences - Australia |
| 8 | SANTA MARIA-VASQUEZ, LORENA IVETTE | Mujer |
Universidad de Chile - Chile
|
| 9 | Alliende, Angelica M. | Mujer |
Universidad de Chile - Chile
|
| 10 | Slee, Jennie | Mujer |
Govt Western Australia - Australia
Government of Western Australia - Australia |
| 11 | Godler, David E. | Hombre |
Royal Childrens Hosp - Australia
Univ Melbourne - Australia Royal Children's Hospital, Melbourne - Australia Faculty of Medicine, Dentistry and Health Sciences - Australia |
| 12 | Baker, Emma K. | Mujer |
Royal Childrens Hosp - Australia
Univ Melbourne - Australia La Trobe Univ - Australia Murdoch Childrens Res Inst - Australia Royal Children's Hospital, Melbourne - Australia Faculty of Medicine, Dentistry and Health Sciences - Australia La Trobe University - Australia |
| Fuente |
|---|
| University of Melbourne |
| National Health and Medical Research Council |
| NHMRC |
| Victorian Government's Operational Infrastructure Support Program |
| Diagnosis and Development group of the Murdoch Children's Research Institute |
| Royal Children's Hospital Foundation |
| Financial Markets Foundation for Children (Australia) |
| Genetics of Learning Disability (GOLD) Service |
| International Postgraduate Research Scholarships (IPRS) |
| Murdoch Children's Research Institute |
| Medical Research Future Fund |
| Financial Markets Foundation for Children |
| Australian Postgraduate Award |
| State Government of Victoria |
| Murdoch Children's Research Institute, Royal Children's Hospital Foundation |
| Next Generation Clinical Researchers Program-Career Development Fellowship - Medical Research Future Fund |
| Foundation for Angelman Syndrome Therapeutics |
| Foundation for Prader-Willi Research (FPWR) |
| Foundation for Angelman Syndrome Therapeutics (FAST; Australia) |
| Research Training Program Fee offset scholarship - University of Melbourne |
| Foundation for Prader-Willi Research |
| Agradecimiento |
|---|
| This study was supported by the Victorian Government's Operational Infrastructure Support Program, with the salaries supported by NHMRC project grants (1049299, 1103389 to D.E.G); Murdoch Children's Research Institute, Royal Children's Hospital Foundation (D.E.G.); Next Generation Clinical Researchers Program-Career Development Fellowship, funded by the Medical Research Future Fund (MRF1141334 to D.E.G.); the Financial Markets Foundation for Children (Australia) (no. 2017 - 361 to D.E.G. and D.J.A.); the Foundation for Angelman Syndrome Therapeutics (FAST; Australia to E.K.B.); and the Foundation for Prader-Willi Research (FPWR to D.E.G., D.J.A and E.K.B.). M.J.F. and C.R. were supported by the Genetics of Learning Disability (GOLD) Service. M.A. was supported by an Australian Postgraduate Award, the International Postgraduate Research Scholarships (IPRS) and the Research Training Program Fee offset scholarship awarded by the University of Melbourne, and in part by the Diagnosis and Development group of the Murdoch Children's Research Institute. |
| This study was supported by the Victorian Government’s Operational Infrastructure Support Program , with the salaries supported by NHMRC project grants ( 1049299 , 1103389 to D.E.G); Murdoch Children’s Research Institute, Royal Children’s Hospital Foundation (D.E.G.); Next Generation Clinical Researchers Program-Career Development Fellowship, funded by the Medical Research Future Fund ( MRF1141334 to D.E.G.); the Financial Markets Foundation for Children (Australia) (no. 2017 – 361 to D.E.G. and D.J.A.); the Foundation for Angelman Syndrome Therapeutics (FAST; Australia to E.K.B.); and the Foundation for Prader-Willi Research (FPWR to D.E.G., D.J.A and E.K.B.). M.J.F. and C.R. were supported by the Genetics of Learning Disability (GOLD) Service. M.A. was supported by an Australian Postgraduate Award , the International Postgraduate Research Scholarships (IPRS) and the Research Training Program Fee offset scholarship awarded by the University of Melbourne, and in part by the Diagnosis and Development group of the Murdoch Children’s Research Institute. |